6 psoriatic disease specific risk factors associated with incident cardiovascular events in PsA/PsO patients: PsO area, TJC, SJC, HAQ score, ESR, daily use of NSAIDs @RheumNow #EULAR2022 #ABSTOP0030

NORD-STAR substudy of coagulation and fibrinolytic parameters: 〽️Impairement in eRA ⚡️Biologic parameters restored by ttmt. Effect seemed ▶️ with Biologic vs. MTX + GCs ❕No adjustment on disease activity #OP0059 #EULAR2022 @RheumNow https://t.co/CJHldOimBn

Cdn cohort of #PsA and CV events - u risk factors were associated with MACE and NSAIDS ⬆️ risk and TNFi ⬇️risk and poor HAQ⬆️ risk. #OP0030 @RheumNow @eular_org Too small events, lipids often absent and spanning 30+ yrs.

Once we add adalimumab in MTX-IR RA, can we dial down MTX & still keep control? New data - now in East Asian pts (with already low MTX) says often yes, without ⬆️ADAb. Obviously RA control 1st/2nd/3rd, but prob doesn’t have to be MTX 20 forever in everyone #EULAR2022 @RheumNow https://t.co/aZ0bsgY7dC

Pre-clinical RA TREAT EARLIER Trial: #Plenary OP0070 RDBPCT eval temporary MTX vs PCB in 136 pts with arthralgias >2 weeks at risk for RA (MRI hand/forefoot w/subclinical inflammation) followed for 2 yrs; 1/3 +ACPA. Rx 1 yr can delay but won’t prevent RA. #EULAR2022 @rheumnow https://t.co/v1GWOBFstz

#EULAR2022 TREAT-EARLIER OP0700 Arthralgia + subclinical inflammation in MRI without RA, treated with MTX + depo steroid injection ▶️In High risk patients, delayed development of synovitis, but does not prevent in long-term ▶️Reduction in disease burden on MTX Rx @RheumNow https://t.co/SKlqMQQTui

MIRACLE (love it!) study. High (max tolerated up to 25mg) vs low dose (6-8mg) MTX in combo with ADA in MTX-IR. Low dose non-inferior with better safety. Japanese population so may not be generalisable. @RheumNow #EULAR2022 OP0062 https://t.co/l3CfzzM7mi https://t.co/lkjuoqLY56

• EULAR Abstract Archive